The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis

The JAK2 c.1849G>T (p.V617F) mutation leads to constitutive activation of Janus kinase (JAK)2 and contributes to dysregulated JAK signaling in myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). In the phase 3 Controlled Myelofibrosis Study with Oral JAK Inhibitor Trea...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood
Glavni autori: Deininger, Michael, Radich, Jerald, Burn, Timothy C., Huber, Reid, Paranagama, Dilan, Verstovsek, Srdan
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2015
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4582331/
https://ncbi.nlm.nih.gov/pubmed/26228487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-03-635235
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items